RFL

Rafael Holdings, Inc. (RFL) SWOT Analysis Analysis (2026)

Invetso Score: 5.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update
Overall Score5.35.3
Change0

Strengths

Score: 5.2 (Moderate)

Rafael Holdings’ financial flexibility, continued advancement of its lead clinical program, and recent successful capital raise provide a moderate foundation for future growth, though the company remains in a pre-commercial stage.

Weaknesses

Score:

Rafael Holdings faces high internal risk due to sustained operating losses, negative returns, and reliance on external funding, with no current commercial revenue to offset expenses.

Opportunities

Score:

Rafael Holdings has moderate external growth opportunities, particularly in rare disease drug development and potential pipeline expansion, supported by a strengthened leadership team and financial resources.

Threats

Score:

Rafael Holdings faces high external risk from clinical trial outcomes, regulatory hurdles, and ongoing cash burn, with additional uncertainty from recent leadership transitions.

Overall Score

Score:

Rafael Holdings is moderately positioned, with a strong cash buffer and advancing clinical program offset by persistent operating losses, high dependence on a single late-stage asset, and significant execution and regulatory risks. The company’s future hinges on successful clinical outcomes and prudent capital management.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Rafael Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →